Navigation Links
Cornell researcher seeks clues to how tuberculosis infects cells
Date:12/21/2007

Cornell researchers are using advanced genetic techniques to better understand the relationship between the bacteria that cause tuberculosis and the human immune system defense cells that engulf them.

The researchers have discovered that unlike many bacterial pathogens, Mycobacterium tuberculosis does not react when immune system cells called macrophages initially make contact; but the bacterium's genes become activated minutes after the pathogen is enveloped by a macrophage and contained in one of its membrane-bound compartments called vacuoles.

David Russell, professor of molecular microbiology at Cornell's College of Veterinary Medicine, and colleagues reported in a November issue of the journal Cell Host and Microbe, that increased acidity inside the vacuoles containing the bacteria serves as the trigger for M. tuberculosis genes to express proteins.

The study also compared the responses of M. tuberculosis to a live bacterial vaccine against tuberculosis known as Bacillus Calmette-Guerin (BCG). It found that the two bacteria may each respond differently to the same stimuli and that BCG appears less capable of protecting itself once inside a macrophage. The findings are consistent with the reduced virulence of BCG, which is key to its safety as a vaccine.

The study is a small part of a larger plan to understand the processes that allow the bacteria to survive within macrophages and then to use that knowledge to develop more effective drugs to fight tuberculosis, which currently kills 2 million people worldwide each year. Existing drugs require six to nine months to treat the active disease that invades and replicates within the lungs.

"What we propose is the exploitation of the data obtained from these basic science studies to develop a comprehensive program of drug development that targets bacterial processes critical to survival inside the human host," said Russell.

Russell's lab used gene chips, or micro
'/>"/>

Contact: Sabina Lee
SSL37@cornell.edu
607-255-3024
Cornell University Communications
Source:Eurekalert

Page: 1 2

Related biology news :

1. Cornell will host the Northeast Biofuel Summit, Nov. 11-13
2. First symposium of UN University-Cornell Africa Series to be held at UN
3. Wiggle room: Cornell researcher borrows idea from sperm to provide energy for nanoscale robots
4. Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports
5. Researchers identify proteins involved in new neurodegenerative syndrome
6. Texas researchers and educators head for Antarctica
7. MGH researchers describe new way to identify, evolve novel enzymes
8. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
9. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
10. U of MN researchers discover noninvasive diagnostic tool for brain diseases
11. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...e course of a lifetime, the heart pumps some 250 m...der to do this, the muscle fibers of the heart hav...ed by Dr. Wolfgang Rottbauer, vice chair of the De...Hospital (Chairman: Prof. Dr. H. A. Katus), has di...bility of the smallest muscular unit, the sarcomer...
(Date:11/24/2009)...us Research Institute (LRI) today named 12 new gra...million, recognize innovative work across a broad ...their creativity, novelty, and potential to drive ... and cure the complex disease of systemic lupus. ,...lupus researchers across the nation and include in...
(Date:11/24/2009)...mic-level action of a remarkable class of ring-sha...rs with the Lawrence Berkeley National Laboratory ...ystallography beamline at the Advanced Light Sourc...n gene expression and replication, and are vital t... infectious agents, such as the human papillomavir...
Breaking Biology News(10 mins):New genetic cause of cardiac failure discovered 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4NIMBioS hosts tutorial on optimal control and optimization for biologists 10071 1New Parkinsons Drug Draws Mixed Reviews 58192 1New Parkinsons Drug Draws Mixed Reviews 58192 2New Parkinsons Drug Draws Mixed Reviews 58192 3Minorities Less Likely to Have Blood Pressure Under Control 58190 1Minorities Less Likely to Have Blood Pressure Under Control 58190 2Minorities Less Likely to Have Blood Pressure Under Control 58190 3
...rchers at the University of Southern California (U...ed and expressed, may be the underlying cause for ...he Dec. 12 issue of Public Library of Science One....ge that a broad epigenetic defect is associated wi... M.D., MPH, professor of obstetrics and gynecology...
...s in Scandinavia have discovered that warm-water s...ce thrived in Danish waters during a prehistoric w...ies, such as cod, were also abundant during this p...rt. , Through the study of archaeological materia...s of monasteries, an international group of fisher...
...ogy partner on new aviation-re...er Holdings, Inc.,(OTC Bulletin Board: CTHH) ( htt...ntegrated mobile computing and Wi-Fi communication...ontechnology.com ), a leading,integrator of manage...ce a,major U.S. airline will be accepting delivery...
Other Biology News:USC researchers explore genetic causes for male infertility 2Ancient fish bones reveal impacts of global warming beneath the sea 2Ancient fish bones reveal impacts of global warming beneath the sea 3Ancient fish bones reveal impacts of global warming beneath the sea 4Ancient fish bones reveal impacts of global warming beneath the sea 5CATCHER to be Deployed at Major U.S. Airline 2CATCHER to be Deployed at Major U.S. Airline 3CATCHER to be Deployed at Major U.S. Airline 4
(Date:11/24/2009)... , REYKJAVIK, Iceland, Novembe...c. (Nasdaq: DCGN ) today announced the approval of...ptcy Court for the District of Delaware,(the "Bank... petition for,relief under Chapter 11 of the Unite.... , The orders issued by the Bankruptcy C...
(Date:11/24/2009)... , SHANGHAI, Nov. 24 /PRNewswire-Asia/...ood & Drug Administration (SFDA) has approved ... its oral insulin project,(Nodlin), an innovative ...proval allows Biolaxy to initiate its first phase ...r characteristic of high blood glucose and poor,me...
(Date:11/24/2009)... , , Primary efficacy endpoint has been met... endometrial cancer, , QUEBEC CITY, Nov. 24 /...DAQ: AEZS ; TSX: AEZ) (the "Company"), a global b...apy and oncology, today announced positive efficac...toxic peptide conjugate, AEZS-108 (formerly AN-152...
(Date:11/24/2009)... , SAN DIEGO, Nov. 24, 2009 /PRNewswire-Fir...RNA ) announced today that the company is schedu...alth Care Conference on December 1, 2009 at 11:30 ...New York Palace Hotel in New York City. Jack Lief,... scheduled to provide an overview of the company, ...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
... Integrated Global Services, CAMBRIDGE, Mass., Ap...launches under a new name, Abt Bio-Pharma Solution...es Inc. The company will continue to,provide custo...for the,pharmaceutical, biotechnology, medical dev...proach that blends decades of experience with wide...
...08 Cardium Therapeutics,(Amex: CXM ) and its ope...at,InnerCool has entered into a European commercia...Euromed), a leading distributor of cardiology,medi...romed will have,exclusive marketing, sales and dis...nd for InnerCool,s portfolio of temperature modula...
... 1, 2008 Derma Sciences,Inc (OTC Bulletin Board: ...reported that sales for 2007 were $34.1 million, a...ported for 2006. Gross margins held steady at 34,p... in new products for the,pipeline, and expanding t...ny reported a loss of $2.3 million or $0.09 loss p...
Other Biology Technology:Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc. 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 3Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 5Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 6Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 7Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 8Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 9Derma Sciences Reports Fourth Quarter Year-End Results for 2007 2Derma Sciences Reports Fourth Quarter Year-End Results for 2007 3Derma Sciences Reports Fourth Quarter Year-End Results for 2007 4Derma Sciences Reports Fourth Quarter Year-End Results for 2007 5
T4 Polynucleotide Kinase Exchange Reaction Buffer from Invitrogen
IMAGEQUANT 400 IQTL from GE Healthcare, formerly Amersham Biosciences
IMAGEQUANT 100 WKSTN from GE Healthcare, formerly Amersham Biosciences
FlowTACS Flow Cytometry Apoptosis Detection Kit from R&D Systems
Biology Products: